Latest news
George Kumar: Why Do Only Half of TNBC Patients Respond to Chemotherapy? - OncodailyOncodaily · Fri, 07 Aug 2026 17:35:49 GMTOutcomes in Early-Stage Triple-Negative Breast Cancer With Dose-Dense Doxorubicin and Cyclophosphamide as Part of Pembrolizumab-Based Regimens - jhoponline.comjhoponline.com · Fri, 07 Aug 2026 16:18:45 GMTWhat To Know About the Prognosis for Triple-Negative Breast Cancer—and Your Risk of It Returning - Health.comHealth.com · Fri, 07 Aug 2026 15:46:34 GMT6 Risk Factors That May Increase Your Risk of Triple-Negative Breast Cancer - Health.comHealth.com · Thu, 06 Aug 2026 20:46:51 GMTFDA Clears Trodelvy as First-Line Therapy for TNBC - Clinical Oncology NewsClinical Oncology News · Thu, 06 Aug 2026 19:42:10 GMTClinical Data-Matched Patient Organoids Customize Drug-Resistant TNBC Treatment - Inside Precision MedicineInside Precision Medicine · Thu, 06 Aug 2026 15:00:15 GMTThe Importance of Giving the Most Effective Therapy Upfront in TNBC - onclive.comonclive.com · Mon, 03 Aug 2026 14:55:00 GMTFDA Green-Lights Five New Treatment Options for Breast Cancer - Cancer HealthCancer Health · Mon, 03 Aug 2026 13:01:12 GMT